For Your Patients

• • For Your Patients
  FDA Committee: Rasagiline Rejected as ‘Disease Modifying’ for Parkinson Disease
• • For Your Patients
  Investigators Restore Working Memory in Aged Monkeys
• • For Your Patients
  At Unique ALS Meeting, New Discoveries, Paradigms, and Complexities Are Front and Center
• • For Your Patients
  IOM: Data Lacking on Benefits of Cognitive Therapy for Traumatic Brain Injury
• • For Your Patients
  A New Oral Drug for MS: How Does it Compare?
• • For Your Patients
  Alpha-synuclein Induces Lewy Body Formation and Neuronal Death, Supporting Cell-to-Cell Disease Transmission A New Model for Parkinson Disease?
• • For Your Patients
  News from the ANA Annual Meeting: MS Death Rate Lower with Early Interferon Use, Study Shows
• • For Your Patients
  Adjunct AEDS Cut Sudden Death Risk Seven-Fold in Drug-Resistant Epilepsy
• • For Your Patients
  How Do Epilepsy Patients Fare in the Long-term After Surgery?
• • For Your Patients
  FDA Approves Clobazam for Reducing Lennox-Gastaut Seizures
• • For Your Patients
  News from ECTRIMS/ACTRIMS Fifth Triennial Conference: MS Drugs Take Center Stage at ECTRIMS/ACTRIM: Weighing their Pros and Cons
• • For Your Patients
  New Molecular DNA Test May Help Detect Down Syndrome
• • For Your Patients
  Young Neurologists Express Career Regret
• • For Your Patients
  Meeting Planner
• • For Your Patients
  Policy Watch: Will a New Reimbursement Model be Coming to Your Area? Massachusetts Program Gains Traction